Validation of Clinical Outcome Measures Specific to mTBI-Related Oculomotor Disorders
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Katie Holmbeck, BS
- Phone Number: 2157801429
- Email: kh3482@drexel.edu
Study Contact Backup
- Name: Mitchell Scheiman, OD, PhD
- Phone Number: 2157801427
- Email: ms5758@drexel.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Recruiting
- The Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of mTBI within previous 1 to 6 months
- Distance visual acuity better than or equal to 20/25 in each eye
- Score >21 on Convergence Insufficiency Symptom Survey
Exclusion Criteria:
- Diagnosis of moderate or severe TBI; > 30-min loss of consciousness
- Not wearing required refractive error)
- Disease(s) known to affect oculomotor system (multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, or Parkinson disease)-Manifest strabismus or intraocular injury (evaluated at vision examination)
- Cognitive delays that may impact testing
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
control participants
no history of mTBI
|
|
mTBI group
history of mTBI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with abnormal near point of convergence
Time Frame: Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
The ability to converge the eyes.
A near point rod will be used with a 20/30 column of letters.
The target will be moved towards the participant slowly, and when diplopia occurs, this will be recorded as the NPC break.
The target will then be moved away from the eyes until single vision is regained, and this will be recorded as the NPC recovery.
The unit of measure is cm and the NPC will be measured 3 times, with 10 seconds in between each measure, and averaged for each participant.
|
Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with abnormal positive fusional vergence
Time Frame: Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
Compensatory ability to overcome exophoria.
A handheld prism bar will be used along with a vertical column of 20/30 letters.
The prism will be placed before one eye, and the participant will be asked to maintain clear, single vision.
Participants will then report when the target becomes blurred (blur), then double (diplopia), and finally return to single vision (recovery).
The unit of measure is prism diopters, and it will be measured three times, with 10 seconds in between each measurement, and averaged for each participant.
|
Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
|
Number of participants with abnormal vergence facility
Time Frame: Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
This is a measure of vergence velocity.
Using a 12-base-out and 3-base-in prism, participants will be instructed to regain clear single vision as quickly as possible.
The investigator will count the number of times this can be accomplished in one minut.e
|
Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
|
Number of participants with abnormal accommodative amplitude
Time Frame: Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
A near point rod will be used along with a column of 20/30 letters.
The test will be performed monocularly, first with the left eye covered, and then with the right eye covered.
The target will slowly be moved towards the participant, and the participant will be instructed to report when the target becomes blurred.
The amplitude of accommodation will be measured 3 times, with 10 seconds in between each measure
|
Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
|
Number of participants with abnormal accommodative facility
Time Frame: Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
This test assesses the speed and endurance of accommodation.
A column of 20/30 letter will be used along with a timer, and +2.00D and -2.00D lens flippers.
The test will be performed monocularly.
The +2.00D lens will be placed before the participant's eye, and the participant will be asked to clear the target as quickly as possible.
Once the participant clears the target, the -2.00D lens will be placed before the eye, and the participant will be asked to report when the target becomes clear again.
This will be repeated as many times as possible within one minute.
The investigator will report how many times this occurs in one minute.
|
Baseline and visit 2, which occurs 8 weeks after the baseline visit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mitchell Scheiman, Pennsylvania College of Optometry at Drexel University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Injuries, Traumatic
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Eye Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Cranial Nerve Diseases
- Brain Injuries
- Brain Concussion
- Ocular Motility Disorders
Other Study ID Numbers
Other Study ID Numbers
- 2406010608
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.